Xbrane Biopharma AB (publ) (XBRANE.ST)
SEK 0.19
(1.74%)
SEK 0.19
(1.74%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 112.89 Million SEK | 288.52% |
| 2022 | 29.05 Million SEK | -20.34% |
| 2021 | 36.47 Million SEK | 813.04% |
| 2020 | 3.99 Million SEK | -36.4% |
| 2019 | 6.28 Million SEK | 51.02% |
| 2018 | 4.15 Million SEK | 271.67% |
| 2017 | 1.11 Million SEK | -73.89% |
| 2016 | 4.28 Million SEK | 5.47% |
| 2015 | 4.06 Million SEK | 0.0% |
| 2014 | - SEK | 0.0% |
| 2013 | - SEK | 0.0% |
| 2012 | - SEK | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q3 | 72.09 Million SEK | -18.6% |
| 2024 Q2 | 125.16 Million SEK | -6.78% |
| 2024 Q1 | 95.01 Million SEK | -15.84% |
| 2023 Q4 | 112.89 Million SEK | -31.69% |
| 2023 Q1 | 30.33 Million SEK | 4.4% |
| 2023 FY | 112.89 Million SEK | 288.52% |
| 2023 Q3 | 165.28 Million SEK | -4.76% |
| 2023 Q2 | 173.55 Million SEK | 472.06% |
| 2022 FY | 29.05 Million SEK | -20.34% |
| 2022 Q3 | 31.39 Million SEK | -6.84% |
| 2022 Q2 | 33.7 Million SEK | -2.09% |
| 2022 Q1 | 34.42 Million SEK | -5.62% |
| 2022 Q4 | 29.05 Million SEK | -7.46% |
| 2021 Q1 | 40.79 Million SEK | 921.1% |
| 2021 FY | 36.47 Million SEK | 813.04% |
| 2021 Q4 | 36.47 Million SEK | -8.08% |
| 2021 Q3 | 39.68 Million SEK | 1.7% |
| 2021 Q2 | 39.01 Million SEK | -4.35% |
| 2020 Q1 | 5.64 Million SEK | -10.14% |
| 2020 Q4 | 3.99 Million SEK | -9.59% |
| 2020 Q3 | 4.41 Million SEK | -10.15% |
| 2020 FY | 3.99 Million SEK | -36.4% |
| 2020 Q2 | 4.91 Million SEK | -12.86% |
| 2019 Q2 | 3.66 Million SEK | -92.3% |
| 2019 Q1 | 47.51 Million SEK | 1042.39% |
| 2019 FY | 6.28 Million SEK | 51.02% |
| 2019 Q4 | 6.28 Million SEK | -12.14% |
| 2019 Q3 | 7.14 Million SEK | 95.33% |
| 2018 Q1 | 21.03 Million SEK | 1779.45% |
| 2018 FY | 4.15 Million SEK | 271.67% |
| 2018 Q4 | 4.15 Million SEK | -55.19% |
| 2018 Q3 | 9.28 Million SEK | -74.15% |
| 2018 Q2 | 35.9 Million SEK | 70.71% |
| 2017 Q1 | 4.25 Million SEK | -0.7% |
| 2017 Q2 | 4.41 Million SEK | 3.8% |
| 2017 Q3 | 295.32 Thousand SEK | -93.32% |
| 2017 Q4 | 1.11 Million SEK | 278.91% |
| 2017 FY | 1.11 Million SEK | -73.89% |
| 2016 Q2 | - SEK | 0.0% |
| 2016 Q3 | - SEK | 0.0% |
| 2016 Q4 | 4.28 Million SEK | 0.0% |
| 2016 FY | 4.28 Million SEK | 5.47% |
| 2016 Q1 | - SEK | -100.0% |
| 2015 Q1 | - SEK | 0.0% |
| 2015 Q3 | - SEK | 0.0% |
| 2015 Q4 | 4.06 Million SEK | 0.0% |
| 2015 FY | 4.06 Million SEK | 0.0% |
| 2014 FY | - SEK | 0.0% |
| 2014 Q4 | - SEK | 0.0% |
| 2013 FY | - SEK | 0.0% |
| 2012 FY | - SEK | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Asarina Pharma AB (publ) | 1 Million SEK | -11189.7% |
| BioArctic AB (publ) | 2.15 Million SEK | -5146.143% |
| Modus Therapeutics Holding AB (publ) | - SEK | -Infinity% |
| CombiGene AB (publ) | - SEK | -Infinity% |
| Diamyd Medical AB (publ) | 30.67 Million SEK | -268.078% |
| Elicera Therapeutics AB (publ) | - SEK | -Infinity% |
| OncoZenge AB (publ) | - SEK | -Infinity% |
| Alligator Bioscience AB (publ) | 7.51 Million SEK | -1402.089% |
| Calliditas Therapeutics AB (publ) | 939.5 Million SEK | 87.983% |
| Mendus AB (publ) | 850 Thousand SEK | -13182.0% |
| LIDDS AB (publ) | - SEK | -Infinity% |
| Lipum AB (publ) | 1.76 Million SEK | -6310.96% |
| Magle Chemoswed Holding AB (publ) | 32.58 Million SEK | -246.501% |
| Simris Alg AB (publ) | 90.74 Million SEK | -24.418% |
| Spago Nanomedical AB (publ) | - SEK | -Infinity% |
| Stayble Therapeutics AB (publ) | 850 Thousand SEK | -13182.0% |
| Xspray Pharma AB (publ) | 31.94 Million SEK | -253.388% |
| Ziccum AB (publ) | 286 Thousand SEK | -39374.476% |
| AcouSort AB (publ) | - SEK | -Infinity% |
| Active Biotech AB (publ) | 3 Million SEK | -3663.233% |
| Alzinova AB (publ) | 800 Thousand SEK | -14012.125% |
| Amniotics AB (publ) | - SEK | -Infinity% |
| Camurus AB (publ) | 13.61 Million SEK | -729.332% |
| Cantargia AB (publ) | - SEK | -Infinity% |
| Scandinavian ChemoTech AB (publ) | - SEK | -Infinity% |
| Genovis AB (publ.) | 74.8 Million SEK | -50.916% |
| Guard Therapeutics International AB (publ) | - SEK | -Infinity% |
| Isofol Medical AB (publ) | - SEK | -Infinity% |
| Intervacc AB (publ) | 142 Thousand SEK | -79404.93% |
| Kancera AB (publ) | - SEK | -Infinity% |
| Karolinska Development AB (publ) | - SEK | -Infinity% |
| Lipigon Pharmaceuticals AB (publ) | - SEK | -Infinity% |
| NextCell Pharma AB | - SEK | -Infinity% |
| Saniona AB (publ) | 65.23 Million SEK | -73.054% |
| Vicore Pharma Holding AB (publ) | - SEK | -Infinity% |
| Xintela AB (publ) | - SEK | -Infinity% |
| Sprint Bioscience AB (publ) | - SEK | -Infinity% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | - SEK | -Infinity% |
| Corline Biomedical AB | - SEK | -Infinity% |
| IRLAB Therapeutics AB (publ) | 24.51 Million SEK | -360.597% |
| Bio-Works Technologies AB (publ) | - SEK | -Infinity% |
| Aptahem AB (publ) | - SEK | -Infinity% |
| Infant Bacterial Therapeutics AB (publ) | - SEK | -Infinity% |
| Fluicell AB (publ) | - SEK | -Infinity% |
| Biovica International AB (publ) | 4.29 Million SEK | -2527.956% |
| Abliva AB (publ) | 424 Thousand SEK | -26526.651% |
| Egetis Therapeutics AB (publ) | 103.4 Million SEK | -9.185% |
| 2cureX AB (publ) | - SEK | -Infinity% |
| I-Tech AB | - SEK | -Infinity% |
| Hansa Biopharma AB (publ) | 844.9 Million SEK | 86.638% |
| Cyxone AB (publ) | 74 Thousand SEK | -152463.514% |
| ExpreS2ion Biotech Holding AB (publ) | 1.43 Million SEK | -7761.908% |
| Biosergen AB | - SEK | -Infinity% |
| Nanologica AB (publ) | 136 Thousand SEK | -82912.5% |
| SynAct Pharma AB | 58 Thousand SEK | -194550.0% |
| Annexin Pharmaceuticals AB (publ) | - SEK | -Infinity% |
| BioInvent International AB (publ) | 14.53 Million SEK | -676.725% |
| Oncopeptides AB (publ) | 106.48 Million SEK | -6.02% |
| Pila Pharma AB (publ) | - SEK | -Infinity% |
| Ascelia Pharma AB (publ) | 176 Thousand SEK | -64046.023% |
| Diagonal Bio AB (publ) | - SEK | -Infinity% |